Temi della conferenza
With strong effectiveness profiles and 20 years of FDA approval, kinase inhibitors have revolutionized oncology treatment. The success of current kinase inhibitor classes is nevertheless constrained by rising resistance and security concerns.
Scientific organizer
Hanson Wade
Annotazioni
Speakers: Erik Schaefer, Co-Founder, President, Chief Executive Officer and Chief Scientific Officer, AssayQuant Technologies Inc., Gerhard Mueller, Chief Scientific Officer, Anavo Therapeutics, Harish Dave, Chief Medical Officer, AUM Biosciences
Informazioni ed Iscrizioni:
https://go.evvnt.com/1446853-3?pid=4832
Mr. Min Ratcliffe
CategorieSanità Pubblica (Public Health), Servizi sanitari